Neutrophil Lymphocyte Ratio as a Predictor of Outcome in Critically Traumatic Patients

Critical Care Clinical Trial

Official title:

Neutrophil Lymphocyte and Platelet Lymphocyte Ratios as Predictors of Outcome in Traumatic Critically Ill Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02749487
• Other study ID #: IRB00009905
• Status: Completed
• Phase: N/A
• First received: April 21, 2016
• Last updated: December 15, 2016
• Start date: June 2015
• Est. completion date: September 2016

Study information

• Verified date: December 2016
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Neutrophil lymphocyte ratio NLR is an important index that evaluate the inflammatory status . It is a cost effective and readily available , and simply calculated , so that why investigators try to use it as a predictor of short term survival in the critically ill patients

Description:

NLR will be used as predictor for short term survival and patients stay in ICU in 2 groups of patients . Investigators will use it in a group of Medical Critically ill patients as respiratory failure , neuromuscular disorders , renal impairment . the other group is the critically ill surgical patients , as patients with multiple trauma , post major surgery

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: September 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Critically ill trauma patients

Exclusion Criteria:

• auto immune disease endocrine disease renal dysfunction hepatic dysfunction malignancy smoking

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Critical Care

Intervention

Other:
• Neutrophil Lymphocyte Ratio
Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.

Locations

Country	Name	City	State
Egypt	Emad Zarief Kamel Said	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	short term survival		one month	No